Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016068 · ClinicalTrials.gov registry record · Phase 3
Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation
A Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT00016068 is a Phase 3 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 184 participants.
The verdict
NCT00016068, a Phase 3 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in preventing cytomegalovirus in patients who have undergone donor stem cell transplantation.
Interventions
- DRUG ganciclovir
- DRUG valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2001-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016068
The ClinicalTrials.gov registry entry for NCT00016068 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ganciclovir is the first listed.
NCT00016068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016068 about?
NCT00016068 is a clinical study titled "Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation". RATIONALE: Antivirals such as valganciclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valganciclovir is effective in preventing cytomegalovirus. PURPOSE: This randomized phase III trial is studying valganciclovir to see how well it works in prev...
What is the current status of trial NCT00016068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2001-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00016068?
The interventions under investigation include: ganciclovir (DRUG), valganciclovir (DRUG).
Who is sponsoring clinical trial NCT00016068?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.